|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Article |
1 Department of Molecular and Cell Genetics, Graduate School of Medical Science, Tottori University, Tottori, Japan
2 Department of Human Genome Sciences (Kirin Brewery), Graduate School of Medical Science, Tottori University, Tottori, Japan
3 Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medicine, Tottori University, Tottori, Japan
4 Department of Tissue Regeneration, Institute for Frontier Medical Science, Kyoto University, Kyoto, Japan
* To whom correspondence should be addressed. E-mail: oshimura{at}grape.med.tottori-u.ac.jp.
| Abstract |
|---|
Mesenchymal stem cells (MSC) hold promise for use in adult stem cell-mediated gene therapy. One of the major aims of stem cell-mediated gene therapy is to develop vectors that will allow appropriate levels of expression of therapeutic genes along differentiation under physiological regulation of the specialized cells. Human artificial chromosomes (HACs) are stably maintained as independent chromosomes in host cells and should be free from potential insertional mutagenesis problems of conventional transgenes. Therefore, HACs have been proposed as alternative implements to cell-mediated gene therapy. Previously, we constructed a novel HAC, termed as 21
pq HAC, with a loxP site in which circular DNA can be reproducibly inserted by the Cre/loxP system. We here assessed feasibility of lineage-specific transgene expression by the 21
pq HAC vector, utilizing in vitro differentiation system with a MSC cell line, hiMSC, which has potential for osteogenic, chondrogenic, and adipogenic differentiation. An EGFP gene driven by a promoter for osteogenic lineage-specific osteopontin (OPN) gene was inserted onto the 21
pq HAC, and then was transferred into hiMSC. The expression cassette was flanked by the chicken HS4 insulators to block promoter interference from adjacent drug resistant genes. The EGFP gene was specifically expressed in the hiMSC that differentiated into osteocytes in coordination with the transcription of endogenous OPN gene, but was not expressed after adipogenic differentiation induction or in non-induction culture. These results suggest that use of the HACs vector is suitable for regulated expression of transgenes in stem cell-mediated gene therapy.
This article has been cited by other articles:
![]() |
M. Paulis, M. Bensi, D. Orioli, C. Mondello, G. Mazzini, M. D'Incalci, C. Falcioni, E. Radaelli, E. Erba, E. Raimondi, et al. Transfer of a Human Chromosomal Vector from a Hamster Cell Line to a Mouse Embryonic Stem Cell Line Stem Cells, October 1, 2007; 25(10): 2543 - 2550. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Haupt, F. Edenhofer, M. Peitz, A. Leinhaas, and O. Brustle Stage-Specific Conditional Mutagenesis in Mouse Embryonic Stem Cell-Derived Neural Cells and Postmitotic Neurons by Direct Delivery of Biologically Active Cre Recombinase Stem Cells, January 1, 2007; 25(1): 181 - 188. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
